Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

• Status: RECRUITING
• Trial end date: 2028-12-01

Summary

SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.

• Phase: PHASE3

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Collaborator: Horizon 2020 - European Commission
• Treatments: Carboplatin; Paclitaxel